DeepMind CEO Demis Hassabis predicts that advances in Artificial Intelligence will sharply accelerate drug discovery, potentially reducing timelines that currently take years down to months. Hassabis, who also leads Isomorphic Labs, a division focused on applying Artificial Intelligence to therapeutics, said he expects significant progress over the next couple of years and even suggested development could become faster than that.
Isomorphic Labs has already established partnerships with major pharmaceutical companies, including Eli Lilly and Novartis. The company is pursuing programs targeting cancer and immune disorders, indicating an early focus on complex therapeutic areas. The article notes that these collaborations are active efforts to translate computational advances into tangible drug development programs, though it does not provide technical details about methods or specific candidate molecules.
The piece frames Hassabis´s comments as an optimistic timeline for the pharmaceutical industry but does not include independent data or milestones to substantiate the schedule. It highlights an intent to shorten the time needed to develop new medicines and to accelerate discovery work through closer industry partnerships. The article also carries a platform disclaimer that the news content may be generated in whole or in part by Artificial Intelligence and may not have been reviewed or fact checked by human editors, advising readers to verify facts before acting on them.
